U.S. markets closed

PTC Therapeutics, Inc. (PTCT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
46.25+0.26 (+0.57%)
At close: 04:00PM EST
46.25 0.00 (0.00%)
After hours: 04:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Slow Stochastic

Slow Stochastic

Previous Close45.99
Bid45.11 x 800
Ask47.65 x 1000
Day's Range45.48 - 46.75
52 Week Range25.01 - 55.58
Avg. Volume670,914
Market Cap3.375B
Beta (5Y Monthly)0.34
PE Ratio (TTM)N/A
EPS (TTM)-7.38
Earnings DateFeb 20, 2023 - Feb 24, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est50.36
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for PTCT

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • PTC Therapeutics, Inc.
    The Argus Min Vol Model PortfolioRapidly rising inflation 2022 knocked stocks into a bear market. While growth strategies suffered the most, value strategies also declined. Even bond prices were lower last year. Volatility, which has dropped from the highs of 2020, still has not returned to pre-COVID levels. Is it time for investors to cash in their chips? We note that investors exit the stock market at their own peril, as long-term returns from equities consistently have outpaced long-term returns from other asset classes, such as fixed income and cash. As well, those fixed-income returns are from eras when the 10-year Treasury bond yield was much higher than the current 3.5% level. So what's a potential equity strategy for investors amid all the uncertainty? Argus believes that Min Vol is an all-weather strategy that is timely in any investing climate.
    Fair Value
    Economic Moat
    3 days agoArgus Research
View more
  • PR Newswire

    NICE Recommends Reimbursement for Translarna™

    PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the National Institute for Health and Care Excellence (NICE) has issued a Final Evaluation Document recommending Translarna™ (ataluren) for reimbursement and use across the National Health Service (NHS) in England and Wales. Translarna is the only approved treatment for patients with nonsense mutation Duchenne muscular dystrophy aged 2 years and older who can walk.

  • PR Newswire

    PTC Therapeutics Launches 9th Annual STRIVE™ Awards Program to Fund Initiatives Benefitting the Duchenne Muscular Dystrophy Community

    PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the launch of the ninth annual STRIVE™ awards program. Through this program, PTC awards grants to patient advocacy organizations who are committed to developing initiatives that address the needs of the Duchenne Muscular Dystrophy (Duchenne) community. Organizations may submit entries to fund 2023 projects focused on one of two categories: Innovation or Transition to Adulthood.

  • PR Newswire

    PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Jan. 5, 2023, the company approved non-statutory stock options to purchase an aggregate of 39,585 shares of its common stock and 13,045 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to 33 new employees. The awards were made pursuant to the NASDAQ inducement grant exception as a component of the new hires' employment compensation.